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Background 
The risk of severe COVID-19 disease is known to be higher in older individuals and those with 
underlying health conditions. Understanding the number of individuals at increased risk of severe 
COVID-19 illness, and how this varies between countries may inform the design of possible strategies 
to shield those at highest risk. 
Methods 
We estimated the number of individuals at increased risk of severe COVID-19 disease by age (5-year 
age groups), sex and country (n=188) based on prevalence data from the Global Burden of Disease 
(GBD) study for 2017 and United Nations population estimates for 2020. We also calculated the 
number of individuals without an underlying condition that could be considered at-risk because of 
their age, using thresholds from 50-70 years. The list of underlying conditions relevant to COVID-19 
disease was determined by mapping conditions listed in GBD to the guidelines published by WHO 
and public health agencies in the UK and US. We analysed data from two large multimorbidity 
studies to determine appropriate adjustment factors for clustering and multimorbidity.  
Results 
We estimate that 1.7 (1.0 - 2.4) billion individuals (22% [15-28%] of the global population) are at 
increased risk of severe COVID-19 disease. The share of the population at increased risk ranges from 
16% in Africa to 31% in Europe. Chronic kidney disease (CKD), cardiovascular disease (CVD), diabetes 
and chronic respiratory disease (CRD) were the most prevalent conditions in males and females aged 
50+ years. African countries with a high prevalence of HIV/AIDS and Island countries with a high 
prevalence of diabetes, also had a high share of the population at increased risk. The prevalence of 
multimorbidity (>1 underlying conditions) was three times higher in Europe than in Africa (10% vs 
3%). 
Conclusion 
Based on current guidelines and prevalence data from GBD, we estimate that one in five individuals 
worldwide has a condition that is on the list of those at increased risk of severe COVID-19 disease. 
However, for many of these individuals the underlying condition will be undiagnosed or not severe 
enough to be captured in health systems, and in some cases the increase in risk may be quite 
modest. There is an urgent need for robust analyses of the risks associated with different underlying 
conditions so that countries can identify the highest risk groups and develop targeted shielding 
policies to mitigate the effects of the COVID-19 pandemic. 
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Research in context  
Evidence before this study 
As the COVID-19 pandemic evolves, countries are considering policies of ‘shielding’ the most 
vulnerable, but there is currently very limited evidence on the number of individuals that might need 
to be shielded. Guidelines on who is currently believed to be at increased risk of severe COVID-19 
illness have been published online by the WHO and public health agencies in the UK and US. We 
searched PubMed ("Risk factors" AND "COVID-19") without language restrictions, from database 
inception until April 5, 2020, and identified 62 studies published between Feb 15, 2020 and March 
20, 2020.  Evidence from China, Italy and the USA indicates that older individuals, males and those 
with underlying conditions, such as CVD, diabetes and CRD, are at greater risk of severe COVID-19 
illness and death.  
Added value of this study 
This study combines evidence from large international databases and new analysis of large 
multimorbidity studies to inform policymakers about the number of individuals that may be at 
increased risk of severe COVID-19 illness in different countries. We developed a tool for rapid 
assessments of the number and percentage of country populations that would need to be targeted 
under different shielding policies.   
Implications of all the available evidence 
Quantifying how many and who is at increased risk of severe COVID-19 illness is critical to help 
countries design more effective interventions to protect vulnerable individuals and reduce pressure 
on health systems. This information can also inform a broader assessment of the health, social and 
economic implications of shielding various groups.
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Introduction 
Emerging evidence from China, Europe and the USA has shown a consistently higher risk of severe 
COVID-19 disease in older individuals and those with underlying health conditions.1-3 Mild and 
moderate cases are those with symptoms but without evidence of pneumonia or dyspnea, and low 
mortality is expected in this group. Severe cases have those symptoms, would require hospitalisation 
if available, and are at risk of increased mortality.4,5 In a recent report from the USA, underlying 
conditions were reported in 71% (732/1037) of individuals hospitalised with COVID-19 and 94% 
(173/184) of deaths.1 The World Health Organization (WHO) as well as public health agencies in 
countries including the UK and US, have issued guidelines on who is considered to be at increased 
risk of severe COVID-19 illness.6-8 This includes individuals with cardiovascular disease (CVD), chronic 
kidney disease (CKD), diabetes, chronic respiratory disease (CRD) and a range of other chronic 
conditions. Such conditions increase the risk of needing hospital-based treatment such as oxygen 
supplementation or mechanical ventilation. A large proportion of the additional health care burden 
of COVID-19 epidemics is likely to result from infection of those with underlying conditions.  
Identifying at-risk populations is important not only for making projections of the likely health 
burden in countries,9,10 but also for the design of effective strategies that aim to  reduce the risk of 
transmission to people in target groups. This is sometimes termed shielding, defined as “a measure 
to protect extremely vulnerable people by minimising interaction between those who are extremely 
vulnerable and others.”11 It has the potential to reduce mortality in vulnerable groups (direct 
benefits), while at the same time mitigating the expected surge in demand for hospital beds (indirect 
benefits), which is critical where systems risk being strained by the national epidemic. However, 
trying to shield an excessive proportion of a population may strain country resources and reduce the 
overall effectiveness of shielding. A detailed assessment of the number of at-risk individuals can 
inform possible shielding strategies. If a vaccine becomes available in the future, it could also be 
used to inform the process of prioritising different groups, based on risk. 
The aim of this work is to provide global, regional and national estimates of the numbers of 
individuals at increased risk of severe COVID-19 disease by virtue of their underlying medical 
conditions during 2020. The risk of severe COVID-19 disease is not binary, but unless tiered 
approaches are adopted, the criterion for whom to shield is, so our estimates seek to capture all 
those ‘at increased risk’ (UK terminology) or ‘at higher risk’ (US terminology) based on current 
guidelines. 
 
Methods 
Prevalence of underlying health conditions 
We used the list of conditions thought to increase the risk of severe COVID-19 illness, based on 
current guidelines from WHO and public health agencies in the UK and US (supplementary 
appendix)6-8  and mapped these to eleven categories of underlying health conditions in the Global 
Burden of Disease Study (GBD). The mapping was completed by a clinical epidemiologist (CWG). 
Prevalence estimates were extracted for the following disease categories by age, sex and country: 
(1) CVD, including CVD caused by hypertension; (2) CKD, including CKD caused by hypertension; (3) 
CRD; (4) chronic liver disease; (5) diabetes; (6) cancers with direct immunosuppression; (7) cancers 
without direct immunosuppression, but with possible immunosuppression caused by treatment; (8) 
HIV/AIDS; (9) tuberculosis; (10) chronic neurological disorders; and (11) sickle cell disorders.  
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We estimate the current number of individuals with underlying conditions making them at risk of 
severe COVID-19 disease by age (5-year age groups), sex and country for 188 countries. Data on the 
prevalence of underlying conditions were extracted by age, sex and country from the GBD study for 
201712 and combined with United Nations mid-year population estimates for 2020.13 For this 
analysis, older individuals without underlying conditions were not considered to be at increased risk.  
Asthma is relatively common, and mild asthma is not listed as a high risk group for shielding so we 
modified GBD estimates of asthma to account only for moderate-to-severe cases (defined as British 
Thoracic Society Steps 4, 5 and 6).14 Based on published evidence from the UK we assumed these 
were 15% of total asthma cases aged <5 years, 17% aged 5-19 years, 23% aged 20-54 years, and 43% 
in those aged 55+ years.15  
For HIV/AIDS, we included all populations, including those on ART. However, we carried out a 
sensitivity analysis to determine how estimates would change if we removed individuals using anti-
retroviral therapy (ART) for instance if there is found to be no additional risk of HIV in individuals on 
ART. We used WHO national estimates for ART coverage among those living with HIV/AIDS.16   
Proportion with at least one underlying condition relevant to severe COVID-19 disease 
The GBD study provides prevalence estimates for each disease category separately, but not for the 
prevalence of people in at least 1 of these categories. One problem was that diseases may cluster, 
for example if they are causally related, and we incorporated this effect for each country, sex and 
age group (but we omit subscripts for clarity). We first calculated 𝑒, which is the expected 
proportion of individuals with at least one condition assuming that the prevalences of the underlying 
conditions are independent (e.g. the fact that someone has diabetes does not affect their risk of 
getting cancer) as 1 minus the probability of not having any of the conditions c1, c2, c3….i.e. 1 – (1 – 
p_c1) x (1 – p_c2) x (1 – p_c3)…. We then estimated the proportion 𝑃, who have at least one 
underlying condition as 𝑃 = 𝑒 × 𝑟, where 𝑟 is the ratio between the observed and expected 
percentage of individuals with at least one condition. The ratio 𝑟 is drawn from evidence from two 
large cross-sectional multimorbidity studies in Scotland17 and Southern China18 (supplementary 
appendix). 
Adjustment for multimorbidity 
In addition to providing estimates for 𝑟, the studies in Scotland and Southern China were also used 
to calculate the multimorbidity fraction i.e. the proportion of individuals with multiple (two or more) 
underlying conditions among those with at least one, by age group and sex. All analyses were done 
using disease categories that matched as closely as possible to the COVID-19-relevant categories 
defined in our analysis. In both studies this included: CVD (defined as the presence of one or more of 
coronary heart disease, hypertension, cerebrovascular disease, peripheral arterial disease, heart 
failure, or atrial fibrillation); chronic neurological disease (defined as one or more of dementia, 
multiple sclerosis and Parkinson’s disease); and CRD (defined as one or both of chronic obstructive 
pulmonary disease and bronchiectasis). Other COVID-related conditions listed above were counted 
separately. The GBD provide separate estimates for hypertensive heart disease and CKD due to 
hypertension, but it was not possible to make this distinction in the multimorbidity datasets, so all 
hypertension was included in the CVD category. 
Using the data from both studies, we calculated pooled estimates of the ratio 𝑟, and the 
multimorbidity fraction by age and sex (supplementary appendix) and extrapolated these pooled 
estimates to all countries included in the analysis.  
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Inclusion of older individuals without underlying conditions  
Some countries have also considered older age as proxy for frailty and increased risk of severe 
COVID-19 illness. Although frailty correlates much more closely with mortality than chronological 
age, there is a well-established non-linear association between increasing age and frailty.19 We 
therefore calculated the number of individuals without an underlying condition that could be 
considered at-risk because of their age, using age thresholds ranging from 50-70 years. All age 
thresholds were evaluated in all regions. To calculate the total number at increased risk for different 
age thresholds, we added the number of older individuals without underlying conditions to our 
earlier estimates of the number of individuals with at least one underlying condition. 
Uncertainty 
We generated low and high estimates using the lower and upper 95% confidence limits for the 
country population size, individual disease prevalences and age-specific multimorbidity fraction. We 
also varied 𝑟, the ratio between the observed and expected percentage of individuals with at least 
one condition, by a range informed by the multimorbidity studies. 
All analyses are provided in an Excel spreadsheet, available at 
https://cmmid.github.io/topics/covid19/. 
 
Results 
Individuals with at least one underlying condition at risk of severe COVID-19 disease 
We estimate that 1.7 billion (1.0 - 2.4) individuals (22% [15-28%] of the global population) have at 
least one underlying condition that could increase their risk of severe COVID-19 disease (table 1, 
supplementary appendix). This value does not include older individuals without underlying 
conditions. The prevalence of one or more condition was approximately 10% by age 25 years, 33% 
by 50 years, and 66% by 70 years, and similar for males and females (figure 1). The most prevalent 
conditions in those aged 50+ years were CKD, CVD, CRD and diabetes. 
Based on crude proportions without age-standardisation, the share of the population at-risk ranged 
from 16% in Africa to 31% in Europe (table 1)(figures 2 and 3). The highest estimates were in 
European and other high-income countries with a high prevalence of CKD, CVD, diabetes and CRD in 
older ages. African countries with a high prevalence of HIV/AIDS and Island countries with a high 
prevalence of diabetes, also had a high share of the population at increased risk.  
In African countries with high HIV prevalence excluding those on ART reduced the at-risk proportion 
e.g. from 27 to 20% in Botswana, 30 to 24% in Lesotho, 27 to 23% in South Africa and 29 to 19% in 
Swaziland. 
We estimate that 23% (range 15-38%) of the working age population (15-64 years) have at least one 
underlying condition (figure 4). This proportion was particularly high in some European countries, 
and Island countries with high rates of diabetes (figure 3). CKD and diabetes were the most common 
conditions in this age range.    
Individuals with multimorbidities associated with severe COVID-19 disease 
Among the 1.7 billion individuals estimated to be at increased risk, we estimate that 0.4 billion (0.2 – 
0.7) individuals (6% [3-8%] of the global population) are living with two or more conditions relevant 
to COVID-19 outcomes in the year 2020 (table 1, supplementary appendix). As expected, this 
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proportion was higher in regions with an older age profile. The prevalence of multimorbidity (two or 
more underlying conditions) was three times higher in Europe than in Africa (10% vs 3%) (table 1). 
Inclusion of older individuals without underlying conditions 
The number of individuals without an underlying condition that could be considered at-risk solely 
because of their age varied by region and choice of age threshold (table 1). In Africa, around 5% of 
individuals aged 50+ years are estimated to have no underlying conditions linked to severe COVID-19 
disease. A similar proportion is estimated at age 65+ years in Europe, North America and Oceania, 
and at 60+ years in Asia and Latin America.   
New analysis of cross-sectional multimorbidity studies 
The ratio 𝑟 was broadly consistent by age, sex and study (supplementary appendix). When 
extrapolating this value to other countries, we used a transparent ratio of 0.9 for all age groups and 
varied this between 0.7 and 1.0 in our low and high estimates. The resulting national estimates of 𝑃 
were constrained to be no less than each country’s single most prevalent condition.  
We estimated that <10% of individuals with underlying conditions have multiple conditions before 
30 years of age, but this increased to about 40% by age 70 years (supplementary appendix). The 
most common combinations in both studies were CVD plus diabetes, CVD plus CKD and CVD plus 
CRD.  
Discussion 
Based on current guidelines and prevalence estimates from GBD, we calculate that one in every five 
individuals worldwide has a condition that is on the list of those at increased risk of severe COVID-19 
disease. However, for many of these individuals the underlying condition will be undiagnosed or not 
severe enough to be captured in health systems. Indeed, most will not progress to severe COVID-19 
disease or death if infected with SARS-Cov-2.1 However, because severe COVID-19 outcomes are 
disproportionately found in individuals with underlying conditions,1 protecting these groups may be 
one of the most effective ways to reduce mortality and demand for hospital beds.20   
Our estimates of the numbers at-risk are based on prevalence estimates extracted from the GBD. 
The GBD study produces estimates of disease prevalence for all ages, both sexes, and for 195 
territories and countries from 1990-2017.21 Because the GBD produces internally comparable 
estimates for a comprehensive list of diseases, these estimates are well suited to compare 
prevalence of disease across locations.  
A recent analysis from Sweden22 provides an opportunity to evaluate our method, and compare GBD 
prevalence estimates to those derived from electronic health record (EHR) data. When we applied 
our method, based on the calculation of 𝑒 and 𝑟, to the prevalence of each condition reported in the 
study, we were able to reproduce the same percentage share of the population at increased risk. 
This provides some reassurance that our method will provide a reasonable approximation of the at-
risk proportion if the same input data on disease prevalence is used. The GBD prevalence estimates 
for Sweden were substantially higher than the estimates from the EHR data, and so we estimate a 
much higher proportion of the population to be at increased risk (35 vs 22%). Many of the prevalent 
cases estimated by GBD would not have been severe enough to be recorded in EHRs, which is likely 
the major reason for the difference. For example, over half of the CKD cases included in GBD 
prevalence estimates represent early stage disease (CKD stage 1 or 2) which is common and rarely 
has symptoms.23 Several other underlying conditions estimated by GBD are also likely to be 
undiagnosed in many individuals e.g. hypertensive heart disease, compensated chronic liver disease, 
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early onset diabetes etc. This has important implications for the interpretation of our estimates 
because it suggests, based on this initial comparison exercise for one country, that around one-third 
of those estimated to have an underlying condition may be undiagnosed or not severe enough to be 
captured in EHRs. For these individuals, shielding policies may not identify them, and perhaps more 
importantly, their increase in risk may be quite modest.  
If a safe and effective vaccine is produced, then our estimates provide an indication of the volumes 
that would be required for vaccination of at-risk individuals globally. In the absence of a vaccine, a 
key option to mitigate the pandemic is to shield at-risk individuals by more intensive physical-
distancing measures than those in the wider population. This may be especially important at times 
and places where health systems risk being overwhelmed by cases. Other infection control measures 
include provision of personal protective equipment and intensive testing of health and social care 
workers in maximum contact with at-risk individuals. At a minimum, timely and effective 
communication should be provided to communities on who within them is at increased risk. Among 
those who are identified, governments will rely heavily on their adherence to guidelines. This would 
allow practical individual-level steps to be taken, such as increased hygiene, physical isolation and 
home-delivered food and medical care.6 As more evidence emerges on the risk associated with 
different conditions, guidelines could be refined and shielding policies tailored to different risk 
groups e.g. isolation for those at very high risk, and less stringent measures (e.g. social distancing) 
for those with a lower level of increased risk. Community-level shielding approaches, including 
vacating houses or public buildings to physically isolate small groups of people at increased risk, may 
also be considered, though these will require stringent infection control arrangements, especially in 
crowded settings,24 and adherence may be low if at-risk individuals are daily wage earners or people 
caring for children e.g. grandparents.25  
The association between the prevalence of underlying conditions and other national characteristics, 
such as economic development, is complex. The prevalence of many of these conditions (HIV/AIDS 
may be an exception) reflect the epidemiological transition26 but survival with these conditions may 
reflect the performance of the health system.27 Hence, it is important to look at the data for each 
country, which goes beyond what we can report in this paper. We provide a spreadsheet tool 
(available at https://cmmid.github.io/topics/covid19/) that can be used for rapid assessment (and 
visualisation) of the estimated number and percentage of country populations targeted under 
different shielding policies. This allows different health conditions to be included/excluded, different 
age thresholds to be assessed, and different choices about key assumptions e.g. estimates of the 
ratio 𝑟, and the multimorbidity fraction by age. Prevalence data included in our spreadsheet can be 
updated as more evidence emerges on the importance (or otherwise) of specific conditions and their 
severities e.g. early stage CKD, simple hypertension etc. 
Our analysis found a substantial number of at-risk individuals in the working age range. Strict 
shielding measures could cause considerable economic disruption to these individuals and their 
families and have a detrimental effect on the wider economy. For some at-risk individuals, 
particularly daily wage earners in low-income countries, it will be important to have alternative 
options to isolation. For example, there is growing evidence in support of face-masks as a means to 
prevent transmission by those wearing them.28 If proven to be effective, or other measures 
emerge,29 this could be a practical way of reducing exposure among those who are unable to avoid 
contact with others. Alternative shielding approaches, so that target groups are supported to reduce 
physical contacts (e.g. through incentives to reduce or abstain from work), can also be considered.  
We based our analysis on underlying conditions listed in guidelines published by the WHO and public 
health agencies in the UK and US. As with seasonal influenza vaccination, these guidelines tend not 
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to be exhaustive, and deliberately permit clinical judgement. As our understanding of this disease 
evolves, it should be possible to provide greater clarity on the risk of severe COVID -19 disease 
associated with different underlying conditions at different severities e.g. early stage CKD, 
compensated liver cirrhosis, moderately severe asthma etc.6 A detailed multivariate analysis of risk is 
urgently needed because nearly all underlying conditions are likely to be at least partly confounded 
by age. Knowledge of the mode of action of the virus is increasing rapidly, especially in relation to its 
action on cells with ACE2 receptors other than in the lung, in particular in the endothelium and 
pancreas, which the inflammatory processes associated with diabetes may be involved in cytokine 
storms that can be fatal.30 
We estimated a similar number of males and females to be at increased risk, although early evidence 
from China, and later studies in other countries show a higher proportion of deaths in males.31 
Earlier research in mice infected with SARS coronavirus also found an increased male susceptibility 
mediated by differences in oestrogen receptor signalling,32 while others have noted the 
concentration of genes involved in the immune system on the x chromosome.33 This is a clearly 
priority for further research. 
We focused our analysis on the list of underlying chronic causes of disease available in GBD2017, 
and did not include risk factors, such as pregnancy, smoking, under-nutrition, obesity, working in the 
health and social care system, homelessness and general frailty e.g. individuals living in care homes 
and other facilities. The importance of these factors on the severity of COVID-19 is still to be 
determined, although some national guidelines already include frailty in decisions about 
treatment.34 
We found that the age threshold for older people without underlying conditions led to a substantial 
increase in the overall number of people that may be considered at increased risk of severe COVID-
19 disease. Individuals in developing countries may be frailer than those of an equivalent age in 
developed countries, and there may be other societal and economic considerations. Older 
individuals without these underlying conditions could suffer adverse mental health consequences 
from long periods of isolation. However, of the approximately 1 billion individuals aged 50+ years 
that we estimate to be at increased risk of severe COVID-19 disease (table 1) many may not be 
aware of their underlying condition.35 For example, CKD has a very high prevalence in many 
countries, but more than 90% of these cases are likely to be undiagnosed.23 Age thresholds could 
therefore play a critical role in shielding the large number of older individuals without a diagnosis. 
Indeed, while our analysis quantifies numbers who could benefit from shielding, in practice the low 
coverage of diagnosis and treatment for many chronic conditions in low-income settings means that 
the age threshold could largely determine the effective target group.  
With the exception of HIV/AIDS our estimates do not account for the role of treatment or control of 
the underlying condition: for example, while some conditions are less prevalent in Africa than 
Europe, African patients may on average be at higher risk as they have less access to diagnosis and 
effective treatment. It is not yet known whether those with HIV are at increased risk of severe 
disease with COVID-19. Whilst it has been shown that widespread introduction of ART reduced the 
risk of hospitalisation and death associated with seasonal influenza,36 a substantial proportion of 
those on ART remain somewhat immunocompromised.37,38 Recent evidence from South Africa has 
shown that individuals living with HIV have an eight-fold higher risk of pneumonia hospitalisation 
associated with seasonal influenza, and a three-fold higher risk of pneumonia death.39 Until more 
evidence emerges, it may be necessary to include these individuals in shielding strategies, 
irrespective of ART status, with priority given to those not yet receiving treatment.40 
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We used data from two large studies to adjust for multimorbidity. Both studies could underestimate 
the prevalence of some conditions and therefore the extent of multimorbidity, although in Scotland, 
most of the included conditions were well recorded in routine health care, and in the Southern China 
study, underlying conditions were well communicated to patients, whose information was collected 
in a community household survey following a standard protocol. These studies cannot capture the 
global diversity of patterns of multimorbidity, which will differ in regions where, for example, there 
are high prevalences of HIV or sickle cell disorders. As multivariate analysis of the risk of serious 
COVID-19 become available, results that include combinations may provide more nuanced 
information to inform decisions about shielding. 
Over the coming weeks and months, countries will need to determine mitigation strategies for the 
pandemic. Where feasible, shielding strategies could reduce the overall health burden by decreasing 
risk of infection to those most likely to experience severe disease and thus require health care. If 
implemented, shielding of at-risk individuals is likely to be required for several months. This may 
have a substantial impact on working-age people if they and their household contacts are less 
economically active for longer than the general population. 
There is an urgent need for robust analyses of the risks associated with different underlying 
conditions so that countries can identify the highest risk groups and develop targeted shielding 
policies to mitigate the effects of the COVID-19 pandemic.  
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Table 1. Number of individuals in millions (% of total population) at increased risk of severe 
COVID-19 illness by age, number of conditions, region and age threshold 
  Africa Asia Europe 
Latin 
America 
and the 
Caribbean 
Northern 
America Oceania Global 
                
No conditions               
<15 years 519 (39) 1042 (22) 117 (16) 152 (23) 65 (18) 10 (23) 1905 (24) 
15-49 years 534 (40) 1986 (43) 274 (37) 292 (45) 147 (40) 17 (40) 3249 (42) 
50-54 years 25 (2) 184 (4) 33 (4) 23 (4) 14 (4) 2 (4) 281 (4) 
55-59 years 18 (1) 137 (3) 29 (4) 18 (3) 13 (3) 1 (3) 216 (3) 
60-64 years 12 (1) 96 (2) 23 (3) 13 (2) 10 (3) 1 (2) 154 (2) 
65-69 years 7 (1) 69 (1) 16 (2) 8 (1) 7 (2) 1 (2) 108 (1) 
70+ years 7 (0) 74 (2) 23 (3) 10 (2) 9 (2) 1 (2) 123 (2) 
All ages 1121 (84) 3588 (77) 516 (69) 515 (79) 264 (72) 32 (76) 6036 (78) 
                
One condition only               
<15 years 20 (1) 44 (1) 3 (0) 4 (1) 2 (0) 0 (1) 72 (1) 
15-49 years 101 (8) 369 (8) 49 (7) 45 (7) 20 (5) 3 (7) 588 (8) 
50-54 years 14 (1) 83 (2) 14 (2) 10 (2) 7 (2) 1 (1) 128 (2) 
55-59 years 12 (1) 78 (2) 17 (2) 10 (2) 8 (2) 1 (2) 127 (2) 
60-64 years 11 (1) 69 (1) 18 (2) 10 (1) 9 (3) 1 (2) 118 (2) 
65-69 years 8 (1) 62 (1) 18 (2) 8 (1) 9 (2) 1 (2) 105 (1) 
70+ years 11 (1) 93 (2) 40 (5) 15 (2) 17 (5) 1 (3) 178 (2) 
All ages 178 (13) 797 (17) 159 (21) 103 (16) 72 (20) 7 (17) 1316 (17) 
                
Multiple (two or more) conditions             
<15 years 1 (0) 3 (0) 0 (0) 0 (0) 0 (0) 0 (0) 4 (0) 
15-49 years 13 (1) 53 (1) 8 (1) 7 (1) 3 (1) 0 (1) 85 (1) 
50-54 years 4 (0) 23 (0) 4 (1) 3 (0) 2 (0) 0 (0) 35 (0) 
55-59 years 4 (0) 27 (1) 6 (1) 4 (1) 3 (1) 0 (1) 44 (1) 
60-64 years 4 (0) 29 (1) 8 (1) 4 (1) 4 (1) 0 (1) 50 (1) 
65-69 years 4 (0) 33 (1) 9 (1) 4 (1) 5 (1) 0 (1) 56 (1) 
70+ years 9 (1) 80 (2) 37 (5) 13 (2) 16 (4) 1 (3) 156 (2) 
All ages 41 (3) 247 (5) 72 (10) 35 (5) 32 (9) 3 (7) 430 (6) 
                
At increased risk of severe COVID-19 disease  
At least one condition 218 (16) 1044 (23) 231 (31) 137 (21) 104 (28) 10 (24) 1746 (22) 
               
…plus age 50+ years 286 (21) 1605 (35) 356 (48) 209 (32) 157 (43) 16 (37) 2628 (34) 
…plus age 55+ years 261 (20) 1420 (31) 322 (43) 186 (29) 143 (39) 14 (34) 2346 (30) 
…plus age 60+ years 244 (18) 1284 (28) 293 (39) 168 (26) 130 (35) 13 (30) 2130 (27) 
…plus age 65+ years 238 (18) 1199 (26) 288 (39) 160 (25) 131 (35) 12 (29) 2028 (26) 
…plus age 70+ years 230 (17) 1137 (25) 271 (36) 152 (23) 122 (33) 12 (28) 1923 (25) 
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Figure 1. Proportion of individuals with at least one underlying condition by age, sex, country and 
region; and prevalence of each underlying condition by age and region 
 
We excluded latent tuberculosis from our analysis but include it here to show the extent of overall TB that was excluded. 
Only the global estimates (solid black line) and country lines are shown (thin lines), but thin lines are coloured to indicate 
the UN population region they belong to. For example, some African countries (green) have a high HIV prevalence, and 
some Island countries in Oceania (purple) have a high prevalence of diabetes.  
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Figure 2. Population and number of individuals with 1 and 2+ conditions by age and region 
(left); prevalence of 1 and 2+ conditions by age and region (right)  
 
Panels A-F represent each UN population region. The plots on the left side show the population by age (blue 
line), those with only 1 condition (light green area) and those with multiple (two or more) conditions (dark 
green). The plots on the right show prevalence of one and multiple conditions by age.   
 
0.0
50.0
100.0
150.0
200.0
250.0
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
%
of
po
pu
la�
on
Africa
0.0
50.0
100.0
150.0
200.0
250.0
300.0
350.0
400.0
450.0
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
%
of
po
pu
la�
on
Asia
P
op
ul
at
io
n
(m
ill
io
ns
)
0.0
10.0
20.0
30.0
40.0
50.0
60.0
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
P
op
ul
at
io
n
(m
ill
io
ns
)
%
of
po
pu
la�
on
0.0
10.0
20.0
30.0
40.0
50.0
60.0
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
P
op
ul
at
io
n
(m
ill
io
ns
)
%
of
po
pu
la�
on
0.0
5.0
10.0
15.0
20.0
25.0
30.0
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
P
op
ul
at
io
n
(m
ill
io
ns
)
%
of
po
pu
la�
on
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
Un
de
r 5
5 t
o 9
10
to
14
15
to
19
20
to
24
25
to
29
30
to
34
35
to
39
40
to
44
45
to
49
50
to
54
55
to
59
60
to
64
65
to
69
70
to
74
75
to
79
80
to
84
85
to
89
90
to
94
95
plu
s
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Un
de
r 5
5 t
o 9
10
to
14
15
to
19
20
to
24
25
to
29
30
to
34
35
to
39
40
to
44
45
to
49
50
to
54
55
to
59
60
to
64
65
to
69
70
to
74
75
to
79
80
to
84
85
to
89
90
to
94
95
plu
s
P
op
ul
at
io
n
(m
ill
io
ns
)
Age (years)
%
of
po
pu
la�
on
Age (years)
B
C
D
E
F
P
op
ul
at
io
n
(m
ill
io
ns
)
1 condition
2+ conditions
Population
A
Europe
Latin America and the Caribbean
Oceania
Northern America
 . CC-BY 4.0 International licenseIt is made available under a 
 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)
The copyright holder for this preprint this version posted April 22, 2020. .https://doi.org/10.1101/2020.04.18.20064774doi: medRxiv preprint 
15 
 
Figure 3. Proportion of population with underlying conditions relevant to COVID-19 
disease by number of conditions, country and region 
  
Each country is given, grouped by UN population regions. The lighter bars give the percentage of the 
population with 1 underlying condition, and darker the percentage of the population with more than 1 
underlying condition. 
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Figure 4. Proportion of working age population (15-64 years) with at least one underlying 
condition relevant to COVID-19 
 
 
Countries shaded in darker green have a higher proportion of their working age population with at least one 
underlying condition relevant to COVID-19. Lighter shaded countries have a lower proportion of their working 
age population with at least one underlying condition.  
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Supplementary appendix 
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Figure 1. Ratio between observed and expected % of individuals with at least one 
condition by age from multimorbidity studies in Scotland and Southern China 
               
For the analysis of both males and females combined, the mean of all age-specific values of r was 0.92 (range 
0.86 to 0.99) in Scotland and 0.92 (range (0.75 – 1.15) in China. For the main analysis we assumed 0.9 across all 
ages (central estimates) for males and females combined in all countries and varied this between 0.7 (low 
estimates) and 1.0 (high estimates). 
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Figure 2. Multimorbidity fraction among those with at least one condition relevant for 
COVID-19 from cross-sectional studies in Scotland and Southern China 
 
The grey lines represent pooled estimates and 95% confidence intervals based on a 2nd order polynomial 
model fitted to all data points. 
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Figure 3. Percentage of global population at increased risk of severe COVID-19 illness (left 
panel) and influence on global estimates (right panel) when conditions are removed one 
at a time 
 
 
The black shaded bar at the bottom represents the central estimate of the global population that are at 
increased risk. All other bars above show how this value changes when each of the conditions are removed 
one at a time. The most influential conditions are at the top of the bar chart and represent larger areas on the 
map shown on the right side. 
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Table 1. List of conditions included in GBD2017 with potential to increase the risk of 
severe COVID-19 illness 
# Category Causes included in the Global Burden of Disease Study (GBD2017) 
1 HIV/AIDS HIV/AIDS - Drug-susceptible Tuberculosis; HIV/AIDS - Multidrug-resistant Tuberculosis 
without extensive drug resistance; HIV/AIDS - Extensively drug-resistant Tuberculosis; 
HIV/AIDS resulting in other diseases 
2 Tuberculosis* Drug-susceptible tuberculosis; Multidrug-resistant tuberculosis without extensive 
drug resistance; Extensively drug-resistant tuberculosis 
3 Cancers with 
direct immune 
suppression 
Hodgkin lymphoma; Non-Hodgkin lymphoma; Multiple myeloma; Acute lymphoid 
leukemia; Chronic lymphoid leukemia; Acute myeloid leukemia; Chronic myeloid 
leukemia; Other leukemia; Other malignant neoplasms; Myelodysplastic, 
myeloproliferative, and other hematopoietic neoplasms 
4 Cancers with 
possible 
immune 
suppression 
(from 
treatment 
therapy) 
Lip and oral cavity cancer; Nasopharynx cancer; Other pharynx cancer; Esophageal 
cancer; Stomach cancer; Colon and rectum cancer; Liver cancer due to hepatitis B; 
Liver cancer due to hepatitis B; Liver cancer due to hepatitis B; Liver cancer due to 
hepatitis C; Liver cancer due to alcohol use; Liver cancer due to NASH; Liver cancer 
due to other causes; Gallbladder and biliary tract cancer; Pancreatic cancer; Larynx 
cancer; Tracheal, bronchus, and lung cancer; Malignant skin melanoma; Breast 
cancer; Cervical cancer; Uterine cancer; Ovarian cancer; Prostate cancer; Testicular 
cancer; Kidney cancer; Bladder cancer; Brain and nervous system cancer; Thyroid 
cancer; Mesothelioma 
5 Cardio-
vascular 
diseases 
Rheumatic heart disease; Ischemic heart disease; Ischemic stroke; Intracerebral 
haemorrhage; Subarachnoid haemorrhage; Hypertensive heart disease; Non-
rheumatic calcific aortic valve disease; Non-rheumatic degenerative mitral valve 
disease; Other non-rheumatic valve diseases; Myocarditis; Alcoholic cardiomyopathy; 
Other cardiomyopathy; Atrial fibrillation and flutter; Aortic aneurysm; Peripheral 
artery disease; Endocarditis; Other cardiovascular and circulatory diseases; Congenital 
heart anomalies 
6 Chronic 
respiratory 
diseases 
Chronic obstructive pulmonary disease; Silicosis; Asbestosis; Coal workers 
pneumoconiosis; Other pneumoconiosis; Asthma*; Interstitial lung disease and 
pulmonary sarcoidosis 
7 Cirrhosis and 
other chronic 
liver diseases 
Cirrhosis and other chronic liver diseases due to hepatitis B; Cirrhosis and other 
chronic liver diseases due to hepatitis C; Cirrhosis and other chronic liver diseases due 
to alcohol use; Cirrhosis and other chronic liver diseases due to other causes 
8 Diabetes 
mellitus 
Diabetes mellitus type 1; Diabetes mellitus type 2 
9 Chronic kidney 
diseases 
Chronic kidney disease due to diabetes mellitus type 1; Chronic kidney disease due to 
diabetes mellitus type 2; Chronic kidney disease due to hypertension; Chronic kidney 
disease due to glomerulonephritis; Chronic kidney disease due to other and 
unspecified causes 
10 Chronic 
neurological 
disorders 
Alzheimer's disease and other dementias; Parkinson's disease; Multiple sclerosis; 
Motor neuron disease; Other neurological disorders; Idiopathic developmental 
intellectual disability; Down syndrome; Neural tube defects 
11 Sickle cell 
disorders 
Sickle cell disorders 
* we excluded latent tuberculosis and adjusted asthma to better reflect BTS steps 4+. 
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Table 2. Low estimates of the number of individuals in millions (% of total population) at 
increased risk of severe COVID-19 illness by age, number of conditions, region and age 
threshold 
Assumptions: 
• Population estimates:     Lower 95% CI 
• Disease prevalence:     Lower 95% CI 
• Ratio (observed vs expected % with 1+ conditions):  0.7 
• Multimorbidity among those with 1+ conditions:   Lower 95% CI 
  Africa Asia Europe 
Latin 
America 
and the 
Caribbean 
Northern 
America Oceania Global 
                
No conditions               
<15 years 467 (40) 948 (23) 109 (16) 137 (24) 59 (18) 9 (23) 1729 (25) 
15-49 years 508 (43) 1910 (46) 272 (40) 276 (48) 139 (42) 17 (43) 3122 (45) 
50-54 years 27 (2) 195 (5) 36 (5) 24 (4) 15 (5) 2 (4) 299 (4) 
55-59 years 20 (2) 152 (4) 34 (5) 20 (3) 15 (4) 2 (4) 242 (3) 
60-64 years 14 (1) 113 (3) 28 (4) 15 (3) 12 (4) 1 (3) 184 (3) 
65-69 years 9 (1) 87 (2) 22 (3) 11 (2) 9 (3) 1 (2) 139 (2) 
70+ years 11 (1) 109 (3) 40 (6) 15 (3) 15 (5) 2 (4) 192 (3) 
All ages 1056 (90) 3513 (85) 542 (79) 499 (86) 265 (80) 32 (85) 5906 (85) 
                
One condition only               
<15 years 8 (1) 21 (1) 1 (0) 1 (0) 0 (0) 0 (0) 31 (0) 
15-49 years 59 (5) 215 (5) 29 (4) 26 (5) 11 (3) 2 (4) 342 (5) 
50-54 years 9 (1) 52 (1) 9 (1) 7 (1) 4 (1) 0 (1) 81 (1) 
55-59 years 8 (1) 50 (1) 11 (2) 7 (1) 6 (2) 0 (1) 82 (1) 
60-64 years 7 (1) 45 (1) 12 (2) 6 (1) 6 (2) 0 (1) 77 (1) 
65-69 years 6 (0) 41 (1) 12 (2) 5 (1) 6 (2) 0 (1) 71 (1) 
70+ years 8 (1) 67 (2) 30 (4) 11 (2) 13 (4) 1 (3) 130 (2) 
All ages 104 (9) 491 (12) 105 (15) 63 (11) 47 (14) 4 (12) 814 (12) 
                
Multiple (two or more) conditions             
<15 years 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
15-49 years 5 (0) 20 (0) 3 (0) 3 (0) 1 (0) 0 (0) 32 (0) 
50-54 years 2 (0) 11 (0) 2 (0) 1 (0) 1 (0) 0 (0) 17 (0) 
55-59 years 2 (0) 14 (0) 3 (0) 2 (0) 2 (0) 0 (0) 22 (0) 
60-64 years 2 (0) 16 (0) 4 (1) 2 (0) 2 (1) 0 (0) 27 (0) 
65-69 years 2 (0) 18 (0) 5 (1) 2 (0) 3 (1) 0 (0) 31 (0) 
70+ years 5 (0) 45 (1) 22 (3) 7 (1) 9 (3) 1 (2) 89 (1) 
All ages 19 (2) 124 (3) 39 (6) 18 (3) 18 (5) 1 (4) 218 (3) 
                
At increased risk of severe COVID-19 illness           
At least one condition 123 (10) 614 (15) 144 (21) 81 (14) 64 (20) 6 (15) 1032 (15) 
                
…plus age 50+ years 204 (17) 1269 (31) 305 (44) 166 (29) 131 (40) 13 (33) 2088 (30) 
…plus age 55+ years 178 (15) 1074 (26) 268 (39) 142 (24) 116 (35) 11 (29) 1789 (26) 
…plus age 60+ years 157 (13) 923 (22) 234 (34) 122 (21) 101 (31) 10 (25) 1547 (22) 
…plus age 65+ years 136 (12) 722 (17) 187 (27) 97 (17) 83 (25) 7 (19) 1233 (18) 
…plus age 70+ years 131 (11) 681 (17) 175 (25) 92 (16) 77 (24) 7 (18) 1163 (17) 
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Table 3. High estimates of the number of individuals in millions (% of total population) at 
increased risk of severe COVID-19 illness by age, number of conditions, region and choice 
of age threshold 
Assumptions: 
• Population estimates:     Upper 95% CI 
• Disease prevalence:     Upper 95% CI 
• Ratio (observed vs expected % with 1+ conditions):  1.0 
• Multimorbidity among those with 1+ conditions:   Upper 95% CI 
  Africa Asia Europe 
Latin 
America 
and the 
Caribbean 
Northern 
America Oceania Global 
                
No conditions               
<15 years 577 (38) 1140 (22) 126 (16) 169 (23) 72 (18) 10 (23) 2093 (24) 
15-49 years 560 (37) 2059 (40) 279 (34) 308 (43) 156 (38) 17 (38) 3378 (39) 
50-54 years 23 (2) 175 (3) 31 (4) 22 (3) 14 (3) 1 (3) 267 (3) 
55-59 years 16 (1) 126 (2) 26 (3) 16 (2) 12 (3) 1 (3) 197 (2) 
60-64 years 10 (1) 83 (2) 18 (2) 11 (1) 8 (2) 1 (2) 131 (2) 
65-69 years 5 (0) 56 (1) 12 (1) 6 (1) 5 (1) 1 (1) 85 (1) 
70+ years 4 (0) 48 (1) 12 (1) 6 (1) 4 (1) 1 (1) 73 (1) 
All ages 1193 (80) 3686 (72) 504 (62) 538 (74) 271 (66) 32 (71) 6224 (72) 
                
One condition only               
<15 years 26 (2) 61 (1) 4 (0) 4 (1) 2 (0) 0 (1) 96 (1) 
15-49 years 139 (9) 509 (10) 66 (8) 61 (8) 27 (7) 4 (8) 807 (9) 
50-54 years 18 (1) 108 (2) 18 (2) 14 (2) 9 (2) 1 (2) 167 (2) 
55-59 years 16 (1) 100 (2) 22 (3) 13 (2) 11 (3) 1 (2) 162 (2) 
60-64 years 13 (1) 88 (2) 23 (3) 12 (2) 12 (3) 1 (2) 148 (2) 
65-69 years 10 (1) 77 (1) 21 (3) 10 (1) 11 (3) 1 (2) 130 (2) 
70+ years 13 (1) 107 (2) 43 (5) 17 (2) 20 (5) 2 (4) 201 (2) 
All ages 236 (16) 1050 (20) 197 (24) 131 (18) 90 (22) 9 (20) 1712 (20) 
                
Multiple (two or more) conditions             
<15 years 3 (0) 8 (0) 1 (0) 1 (0) 0 (0) 0 (0) 13 (0) 
15-49 years 26 (2) 102 (2) 14 (2) 12 (2) 6 (1) 1 (2) 161 (2) 
50-54 years 6 (0) 38 (1) 6 (1) 5 (1) 3 (1) 0 (1) 58 (1) 
55-59 years 7 (0) 42 (1) 9 (1) 6 (1) 4 (1) 0 (1) 68 (1) 
60-64 years 7 (0) 45 (1) 12 (1) 6 (1) 6 (1) 0 (1) 75 (1) 
65-69 years 7 (0) 48 (1) 13 (2) 6 (1) 7 (2) 0 (1) 82 (1) 
70+ years 14 (1) 118 (2) 52 (6) 19 (3) 23 (6) 2 (4) 228 (3) 
All ages 69 (5) 400 (8) 107 (13) 55 (8) 49 (12) 4 (9) 685 (8) 
                
At increased risk of severe COVID-19 illness           
At least one condition 305 (20) 1450 (28) 304 (38) 186 (26) 139 (34) 13 (29) 2398 (28) 
                
…plus age 50+ years 362 (24) 1937 (38) 404 (50) 247 (34) 182 (44) 18 (39) 3150 (37) 
…plus age 55+ years 339 (23) 1762 (34) 373 (46) 225 (31) 168 (41) 16 (36) 2884 (33) 
…plus age 60+ years 323 (22) 1637 (32) 346 (43) 209 (29) 156 (38) 15 (33) 2686 (31) 
…plus age 65+ years 329 (22) 1634 (32) 369 (46) 213 (29) 169 (41) 16 (35) 2729 (32) 
…plus age 70+ years 319 (21) 1557 (30) 348 (43) 203 (28) 158 (39) 15 (33) 2599 (30) 
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